CDK7 and breast carcinoma: Some other CDK7 inhibitors, for example, SY-1365 and YKL-5-124, show covalent binding to CDK7 and also have low IC50 and positive effects in ovarian and breast cancer, and neuroblastoma, respectively [240,241] (Table 3).